Tiumbio gets nod for hemophilia drug trial in Italy, Spain

Tiumbio CI

Tiumbio, a company dedicated to the development of treatments for rare and intractable diseases, announced on Tuesday that it received approval from both the Italian Medicines Agency (AIFA) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to proceed with a Phase 1b clinical trial for its investigational hemophilia treatment, ‘TU7710.’

The clinical trial is scheduled to begin in August 2024 and will involve 18 hemophilia patients across eight sites in the two countries. The primary focus of the trial will be to evaluate TU7710’s safety and pharmacokinetics.

Tiumbio highlighted that the Phase 1a interim results showed promising data, with the half-life (the time taken for the drug‘s effectiveness to reduce by half) ranging between 10.4 and 16.6 hours. This finding indicates TU7710’s potential as a long-acting therapeutic option for hemophilia patients, who often require frequent dosing with current treatments.